American Riviera
You are here:  Home  >  Biotech  >  Current Article

Amgen buying 20 percent of BeiGene for $2.7 billion

By   /   Thursday, October 31st, 2019  /   Comments Off on Amgen buying 20 percent of BeiGene for $2.7 billion

    Print       Email
In another major M&A deal, Amgen announced plans to purchase around 20 percent of Chinese company BeiGene for $2.7 billion in cash as it works to commercialize its latest oncology products in China. The acquisition represents a purchase price of $174.85 per share of BeiGene, a 26 percent premium over the company’s Oct. 31 closing…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Community Bank of Santa Maria reports income, asset growth

Read More →